Literature DB >> 31004963

Targeted protein degradation: elements of PROTAC design.

Stacey-Lynn Paiva1, Craig M Crews2.   

Abstract

Targeted protein degradation using Proteolysis Targeting Chimeras (PROTACs) has emerged as a novel therapeutic modality in drug discovery. PROTACs mediate the degradation of select proteins of interest (POIs) by hijacking the activity of E3 ubiquitin ligases for POI ubiquitination and subsequent degradation by the 26S proteasome. This hijacking mechanism has been used to degrade various types of disease-relevant POIs. In this review, we aim to highlight the recent advances in targeted protein degradation and describe the challenges that need to be addressed in order to efficiently develop potent PROTACs.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31004963      PMCID: PMC6930012          DOI: 10.1016/j.cbpa.2019.02.022

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  113 in total

Review 1.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694

Review 2.  BET domain co-regulators in obesity, inflammation and cancer.

Authors:  Anna C Belkina; Gerald V Denis
Journal:  Nat Rev Cancer       Date:  2012-06-22       Impact factor: 60.716

3.  p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.

Authors:  Thang Van Nguyen; Jing Li; Chin-Chun Jean Lu; Jennifer L Mamrosh; Gang Lu; Brian E Cathers; Raymond J Deshaies
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-20       Impact factor: 11.205

4.  PROTAC-mediated crosstalk between E3 ligases.

Authors:  Christian Steinebach; Hannes Kehm; Stefanie Lindner; Lan Phuong Vu; Simon Köpff; Álvaro López Mármol; Corinna Weiler; Karl G Wagner; Michaela Reichenzeller; Jan Krönke; Michael Gütschow
Journal:  Chem Commun (Camb)       Date:  2019-02-05       Impact factor: 6.222

5.  RING-between-RINGs--keeping the safety on loaded guns.

Authors:  Katja K Dove; Rachel E Klevit
Journal:  EMBO J       Date:  2012-09-07       Impact factor: 11.598

Review 6.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

Review 7.  Molecular mechanisms of drug resistance.

Authors:  D B Longley; P G Johnston
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

8.  Delineating the role of cooperativity in the design of potent PROTACs for BTK.

Authors:  Adelajda Zorba; Chuong Nguyen; Yingrong Xu; Jeremy Starr; Kris Borzilleri; James Smith; Hongyao Zhu; Kathleen A Farley; WeiDong Ding; James Schiemer; Xidong Feng; Jeanne S Chang; Daniel P Uccello; Jennifer A Young; Carmen N Garcia-Irrizary; Lara Czabaniuk; Brandon Schuff; Robert Oliver; Justin Montgomery; Matthew M Hayward; Jotham Coe; Jinshan Chen; Mark Niosi; Suman Luthra; Jaymin C Shah; Ayman El-Kattan; Xiayang Qiu; Graham M West; Mark C Noe; Veerabahu Shanmugasundaram; Adam M Gilbert; Matthew F Brown; Matthew F Calabrese
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-16       Impact factor: 11.205

9.  Selective Sirt2 inhibition by ligand-induced rearrangement of the active site.

Authors:  Tobias Rumpf; Matthias Schiedel; Berin Karaman; Claudia Roessler; Brian J North; Attila Lehotzky; Judit Oláh; Kathrin I Ladwein; Karin Schmidtkunz; Markus Gajer; Martin Pannek; Clemens Steegborn; David A Sinclair; Stefan Gerhardt; Judit Ovádi; Mike Schutkowski; Wolfgang Sippl; Oliver Einsle; Manfred Jung
Journal:  Nat Commun       Date:  2015-02-12       Impact factor: 14.919

10.  MELK is not necessary for the proliferation of basal-like breast cancer cells.

Authors:  Hai-Tsang Huang; Hyuk-Soo Seo; Tinghu Zhang; Yubao Wang; Baishan Jiang; Qing Li; Dennis L Buckley; Behnam Nabet; Justin M Roberts; Joshiawa Paulk; Shiva Dastjerdi; Georg E Winter; Hilary McLauchlan; Jennifer Moran; James E Bradner; Michael J Eck; Sirano Dhe-Paganon; Jean J Zhao; Nathanael S Gray
Journal:  Elife       Date:  2017-09-19       Impact factor: 8.140

View more
  102 in total

1.  Medicinal Chemistry: From Targets to Therapies.

Authors:  Bruce E Maryanoff; Peter Wipf
Journal:  ACS Med Chem Lett       Date:  2019-07-11       Impact factor: 4.345

Review 2.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 3.  Advances in targeting 'undruggable' transcription factors with small molecules.

Authors:  Matthew J Henley; Angela N Koehler
Journal:  Nat Rev Drug Discov       Date:  2021-05-18       Impact factor: 84.694

4.  Intrinsically disordered linkers control tethered kinases via effective concentration.

Authors:  Mateusz Dyla; Magnus Kjaergaard
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-18       Impact factor: 11.205

Review 5.  Proteolysis-targeting chimeras in drug development: A safety perspective.

Authors:  Kevin Moreau; Muireann Coen; Andrew X Zhang; Fiona Pachl; M Paola Castaldi; Goran Dahl; Helen Boyd; Clay Scott; Pete Newham
Journal:  Br J Pharmacol       Date:  2020-02-25       Impact factor: 8.739

6.  Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines.

Authors:  Xuan Zhang; Yonghan He; Peiyi Zhang; Vivekananda Budamagunta; Dongwen Lv; Dinesh Thummuri; Yang Yang; Jing Pei; Yaxia Yuan; Daohong Zhou; Guangrong Zheng
Journal:  Eur J Med Chem       Date:  2020-05-04       Impact factor: 6.514

7.  A modular PROTAC design for target destruction using a degradation signal based on a single amino acid.

Authors:  Karthigayan Shanmugasundaram; Peng Shao; Han Chen; Bismarck Campos; Stanton F McHardy; Tuoping Luo; Hai Rao
Journal:  J Biol Chem       Date:  2019-09-11       Impact factor: 5.157

8.  The N-terminal domain of the non-receptor tyrosine kinase ABL confers protein instability and suppresses tumorigenesis.

Authors:  Zhengwei Yan; Karthigayan Shanmugasundaram; Dongwen Ma; Jiayu Luo; Shiwen Luo; Hai Rao
Journal:  J Biol Chem       Date:  2020-05-21       Impact factor: 5.157

9.  Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library.

Authors:  Chelsea E Powell; Guangyan Du; Jianwei Che; Zhixiang He; Katherine A Donovan; Hong Yue; Eric S Wang; Radosław P Nowak; Tinghu Zhang; Eric S Fischer; Nathanael S Gray
Journal:  ACS Chem Biol       Date:  2020-09-28       Impact factor: 5.100

Review 10.  Chemical strategies to overcome resistance against targeted anticancer therapeutics.

Authors:  Rudolf Pisa; Tarun M Kapoor
Journal:  Nat Chem Biol       Date:  2020-07-21       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.